Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
" In view of : - the efficacy and safety data versus placebo, - the absence of direct comparative data versus other anti-ANF agents, particularly infliximab, the Transparency Committee considers that SIMPONI (golimumab) does not provide any improvement in actual benefit (IAB V, non-existent) in the treatment of moderately to severely active UC which is resistant to conventional therapies." |
eNq1mF1v2jAUhu/5FVHuSQiDQadAtbF2Q2o1Ros27aYyyaGYBTs9tvnYr59D6AaTo64GX8Z23nPi8/rxUeLLzTLzVoCCctbzo6Dhe8ASnlL22PMn99f1rn/Zr8ULsiIHyzpBI4iavpdkRIieX8wGUyBMBN9vbz6Cfh/Q79e8mE8XkMijdUrSLPhMxPyW5MUaL15xmnpLkHOe9vxcyd2oFwuJOov+muNPkZME4nA/cji7eGgdjsdhIfYfqkoA3hD2aBQFZqWZKERgckAkPHLcVuT7xkqbijEIrjCBEZHzEfIVTSE1hpiRTIBVkNk6vQNcZSCLIEbxcJEshZU4WZDNGJ6G5qTf69mB3Mh6ox51Os1up91qtKJWZBUKD7bKXAX9EWHyEOlArYt2CCwUdJlzRi1rM+IoSeaoKlQMjo3lKA7C04vVT6nIM7INFiK33SqCRE8D6uPv7kOKL7hHDaRM79k/+kxlWfjKrCd7XDjKuKDRgCsmK6hxPbbdiAFnEjbVFbUDndzsvUhBnE/2F2dmyI/UNKOJLdI0dBQIORkPq4l2Thh8IAIm6I4G3yhL+VqcnzKHVXWUfb4DpVE0xzR6aF5030bttvUh+qEtVHHDXCnkOYSaP1ScgpUhm/FTgaJdaZZ69uTZ7Ljrc3hCMqjodOqWbNE+fG7MnDnd3SkqJ4yin67ube3xVQFu73aPRmma9v4U1g68LmiuzViZ+OutXZ5wJz2wQjM55lLm4l0YrtfrYE5EXRC9S8EMz072g8vUXQfu5MYuO5iSjo5Sn5bX3usqZHvSXrrTT+1T9+/v+2FjDIkKTqhFCWVn6BxenZ/Gf5tUZ2mPjujhLsyuoSSScuaq0VFTo+Jp/Nd1ZdeoAfFlNqMVf0QqfRmH5d+Yfi0Oiz8x/dpvH4zlHQ==
y94n9WWm8EjyMYMn
